Show simple item record

dc.contributor.authorGRAY, STEVENen
dc.contributor.authorO'DONNELL, DEARBHAILEen
dc.contributor.authorO'BYRNE, KENen
dc.date.accessioned2011-06-01T16:01:12Z
dc.date.available2011-06-01T16:01:12Z
dc.date.issued2011en
dc.date.submitted2011en
dc.identifier.citationEasty DJ, Gray SG, O'Byrne KJ, O'Donnell D, Bennett DC, Receptor tyrosine kinases and their activation in melanoma., Pigment Cell & Melanoma Research, 24, 3, 2011, 446 461en
dc.identifier.issn1755-1471en
dc.identifier.otherYen
dc.identifier.urihttp://hdl.handle.net/2262/56264
dc.descriptionPUBLISHEDen
dc.description.abstractReceptor tyrosine kinases (RTKs) and their downstream signalling pathways have long been hypothesized to play key roles in melanoma development. A decade ago, evidence was derived largely from animal models, RTK expression studies and detection of activated RAS isoforms in a small fraction of melanomas. Predictions that overexpression of specific RTKs implied increased kinase activity and that some RTKs would show activating mutations in melanoma were largely untested. However, technological advances including rapid gene sequencing, siRNA methods and phospho-RTK arrays now give a more complete picture. Mutated forms of RTK genes including KIT, ERBB4, the EPH and FGFR families and others are known in melanoma. Additional over- or underexpressed RTKs and also protein tyrosine phosphatases (PTPs) have been reported, and activities measured. Complex interactions between RTKs and PTPs are implicated in the abnormal signalling driving aberrant growth and survival in malignant melanocytes, and indeed in normal melanocytic signalling including the response to ultraviolet radiation. Kinases are considered druggable targets, so characterisation of global RTK activity in melanoma should assist the rational development of tyrosine kinase inhibitors for clinical use.en
dc.format.extent446-461en
dc.language.isoenen
dc.relation.ispartofseriesPigment Cell & Melanoma Researchen
dc.relation.ispartofseries24en
dc.relation.ispartofseries3en
dc.rightsYen
dc.subjectOncologyen
dc.subjectmelanomaen
dc.subjectReceptor tyrosine kinases (RTKs)en
dc.titleReceptor tyrosine kinases and their activation in melanoma.en
dc.typeJournal Articleen
dc.type.supercollectionscholarly_publicationsen
dc.type.supercollectionrefereed_publicationsen
dc.identifier.peoplefinderurlhttp://people.tcd.ie/graysten
dc.identifier.peoplefinderurlhttp://people.tcd.ie/obyrnekeen
dc.identifier.peoplefinderurlhttp://people.tcd.ie/odonnedmen
dc.identifier.rssinternalid71276en
dc.identifier.doihttp://dx.doi.org/10.1111/j.1755-148X.2011.00836.xen
dc.subject.TCDThemeCanceren
dc.identifier.rssurihttp://dx.doi.org/10.1111/j.1755-148X.2011.00836.xen
dc.identifier.orcid_id0000-0002-5850-6392en


Files in this item

Thumbnail

This item appears in the following Collection(s)

Show simple item record